Article

Novel Pen-Like Device Distinguishes Between Tumor, Healthy Tissue

Author(s):

Mass spectrometry device rapidly identifies molecular profile of cancerous tissue.

A pen-like device is able to analyze human tissue samples in real-time to determine whether it is cancerous, according to a recent study.

Standard methods for histopathologic tissue diagnosis can be challenging and time-intensive, delaying decision-making. To create a more rapid and nondestructive option, scientists developed a biocompatible handheld mass spectrometry device called MasSpec Pen.

This automated device enables controlled delivery of a discrete water droplet to a tissue surface for extraction of biomolecules.

In a study published in Science Translational Medicine, investigators conducted an ex vivo molecular analysis of 20 human cancer thin tissue sections and 253 human patient tissue samples using the MasSpec Pen. The samples included normal and cancerous tissues from the breast, lung, thyroid, and ovary.

The findings showed the obtained mass spectra presented rich molecular profiles characterized by metabolites, lipids, and proteins.

Statistical classifiers built from the histologically validated molecular database allowed cancer prediction with high sensitivity (96.4%), specificity (96.25), and overall accuracy (96.3%), as well as prediction of benign and malignant thyroid tumors and different histologic subtypes of lung cancer.

Furthermore, the classifier enabled a more accurate diagnosis of cancer in marginal tumor areas with mixed histologic composition. Using mouse models with tumors, the investigators demonstrated the MasSpec Pen was well suited during surgical operations.

“MasSpec Pen could potentially be used as a clinical and intraoperative technology for ex vivo and in vivo cancer diagnosis,” the authors concluded.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC